References

References:
 
1. Congdon NG, Friedman DS, Lietman T. Important Causes of Visual Impairment in the World Today. JAMA. 2003;290(15):2057-2060. doi:10.1001/jama.290.15.2057
 
2. Eye Diseases Prevalence Research Group.  Prevalence of age-related macular degeneration in the United States.  Arch Ophthalmol.2004;122:564-572.
 
3. Bressler NM. Age-Related Macular Degeneration Is the Leading Cause of Blindness. JAMA. 2004;291(15):1900-1901. doi:10.1001/jama.291.15.1900.
 
4. Alfredo Pece, Claudio Azzolini, Maurizio Battaglia Parodi, Ferdinando Bottoni, Paola Danzi, Simone Donati, Ugo Introini, Vincenzo Pucci, Francesco Semeraro, and Francesco Viola. Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. Expert Review of Ophthalmology, June 2012, Vol. 7, No. 3 , Pages 219-225. (doi: 10.1586/eop.12.24).
 
5. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029–36.
 
6. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77–88.
 
7. Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging. 2007;24(8):643–62.
 
8. Hope-Ross M, Yannuzzi LA, Gragoudas ES, TFyer DR, Slakter JS, Sorenson JA, Krupsky S, Orlock DA, Puliafito CA. Adverse reactions due to indocyanine green. Ophthalmology 1994; 101:529-533.
 
9. CHERRICK GR, STEIN SW, LEEVY CM, DAVIDSON CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960 Apr;39:592-600.
10. Baker KJ. Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. Proc Soc Exp Biol Med. 1966 Aug-Sep;122(4):957-63.
 
11. Brown N, Strong R. Infrared fundus angiography. Br J Ophthalmol. 1973 Oct;57(10):797-802.
 
12. Fineman MS, Maguire JI, Fineman SW, Benson WE. Safety of indocyanine green angiography during pregnancy. Arch Ophthalmol 2001; 119:353-355.
 
13. Guyer DR and Yannuzzi LA. Occult choroidal neovascularization. In Flower RW. Indocyanine green angiography.  Yannuzzi LA, Flower RW, Slakter JS. Ed. Mosby. St. Louis, Missouri. 1997; 157-180.
 
14. Guyer DR, Puliafito CA, Mones JM, Friedman E, Chang W, Verdooner SR.  Digital indocyanine-green angiography in chorioretinal disorders. Ophthalmology. 1992 Feb;99(2):287-91. 
 
15.  Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. Retina. 1992;12(3):191-223.
 
16. Kogure K, David NJ, Yamanouchi U, Choromokos E. Infrared absorption angiography of the fundus circulation. Arch Ophthalmol. 1970 Feb;83(2):209-14.
 
17. Flower RW. Injection technique for indocyanine green and sodium fluorescein dye angiography of the eye. Invest Ophthalmol 1973; 12: 881-895.
 
18. Desmettre T, Devoisselle JM, Mordon S. Fluorescence properties and metabolic features of indocyanine green as related to angiography. Surv Ophthalmol 2000; 45:15-27.
 
19. Obana A, Miki T, Hayashi K, Takeda M, Kawamura A, Mutoh T, Harino S, Fukushima I, Komatsu H, Takaku Y. Survey of complications of indocyanine green angiography in Japan.Am J Ophthalmol. 1994;118:749-753.
 
20. Cohen SY, Dubois L, Quentel G, Gaudric A. Retina. Is indocyanine green angiography still relevant?. 2011 Feb;31(2):209-21. doi: 10.1097/IAE.0b013e31820a69db.
 
21. Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. Retina. 1992;12:191–223.
 
22. Yannuzzi LA, Negra˜o S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416–434.
 
23. Hayashi K, Hasegawa Y, Tokoro T, De Laey JJ. Value of indocyanine green angiography in the diagnosis of occult choroidal neovascular membrane. Jpn J Clin Ophthalmol 1988;42:827–829.
 
24. Hayashi K, Hasegawa Y, Tokoro T, De Laey JJ. Clinical appli- cation of indocyanine green angiography to occult choroidal neovascularisation. Jpn J Clin Ophthalmol 1989;43:57–65.
 
25. Sorenson JA, Yannuzzi LA, Slakter JS, Guyer DR, Ho AC, Orlock DA. A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovasculari- zation in age-related macular degeneration. Arch Ophthalmol 1994;112:473–479.
 
26. Slakter JS, Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock DA. A pilot study of indocyanine green video- angiography-guided laser photocoagulation of occult choroi- dal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994;112:465–472. 
 
27. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorio- retinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 1995;113:1392–1398. 
 
28. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neo- ?vascularization: the expanded spectrum of retinal angioma- ?tous proliferation. Retina 2008;28:201–211. 
 
29. Shiraga F, Ojima Y, Matsuo T, Takasu I, Matsuo N. Feeder ?vessel photocoagulation of subfoveal choroidal neovascula- rization secondary to age-related macular degeneration. Ophthalmology 1998;105:662–669. 
 
30. Flower RW. Experimental studies of indocyanine green dye- enhanced photocoagulation of choroidal neovascularization feeder vessels. Am J Ophthalmol 2000;129:501–512. 
 
31. Desatnik H, Treister G, Alhalel A, Krupsky S, Moisseiev J. ICGA-guided laser photocoagulation of feeder vessels of choroidal neovascular membranes in age-related macular degeneration. Indocyanine green angiography. Retina 2000; 20:143–150. 
 
32. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 2000;84:239–243.
 
33. Bressler NM; Treatment of Age-Related Macular Degener- ation with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovasculari-zation in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198–207.
 
34. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age- related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541–560.
 
35.  Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
 
36. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration. N Engl J Med 2006;355:1432–1444.
 
37. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol 2010;4:369–374.
 
38. Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal innerretinal hemorrhages in patients with drusen: an early sign ofoccult choroidal neovascularization and chorioretinal anastomosis. Retina 2003;23:741–751.
 
39. Matsumoto H, Sato T, Kishi S. Tomographic features ofintraretinal neovascularization in retinal angiomatous proliferation. Retina 2010;30:425–430.
 
40. Spaide RF. Enhanced depth imaging optical coherence tomographyof retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol 2009;147:644–652.
 
41. Keane PA, Sadda SR. Imaging chorioretinal vascular disease. Eye (Lond) 2010;24:422–427.
 
42. Arnold JJ, Quaranta M, Soubrane G, Sarks SH, Coscas G.Indocyanine green angiography of drusen. Am J Ophthalmol1997;124:344–356.
 
43. ChangAA,GuyerDR,OrlockDR,Yannuzzi LA.Age-dependent variations in the drusen fluorescence on indocyanine greenangiography. Clin Experiment Ophthalmol 2003;31:300–304.
 
44. Quaranta M, Buglione M, Lo Schiavo Elia R, Coscas G, Soubrane G. Indocyanine green angiography of basal laminar drusen in the retinal pigment epithelium associated with vitelliform macular degeneration. J Fr Ophtalmol1998;21:185–190.
 
45. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina 1995;15:183–191.
 
46. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular disease. Am J Ophthalmol 2009;148:733–743.
 
47. Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurenghi G.
The dark atrophy with indocyanine green angiography in Stargardt disease. Invest Ophthalmol Vis Sci. 2012 Jun 26;53(7):3999-4004. doi: 10.1167/iovs.11-9258.
 
48. Guyer DR, Yannuzzi LA, Slakter JS, et al. Classi?cation of  choroidal neovascularizaton by digital indocyanine green videoangiography. Ophthalmology 1996;103:2054–60.
 
49. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology. 2003 Jan;110(1):15-21; quiz 22-3. Review.
 
50. Guyer DR, Yannuzzi LA, Ladas I, et al. Indocyanine greenguided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization. Arch Ophthalmol.1996;114:693–7.
 
51. Hoang QV, Gallego-Pinazo R, Yannuzzi LA. LONG-TERM FOLLOW-UP OF ACUTE ZONAL OCCULT OUTER RETINOPATHY. Retina. 2013 Apr 15. [Epub ahead of print] PMID: 23591538.
 
52. Sorenson JA, Yannuzzi LA, Slakter JS, Guyer DR, Ho AC, Orlock DA.  A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 1994 Apr;112(4):473-9.
 
53. Coscas G. Chapter III: Age-Related Macular Degeneration . In: ATLAS OF INDOCYANINE GREEN ANGIOGRAPHY FLUORESCEIN ANGIOGRAPHY, ICG ANGIOGRAPHY AND OCT CORRELATIONS. Coscas G.  Pag. 118. Ed. Elsevier  September 2005. ISBN: 2-84299-729-8.
 
54. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993 Jun 15;115(6):786-91. 
 
55. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002 Jun;86(6):663-9.
 
56. Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. 1984. Retina. 2003 Dec;23(6 Suppl):205-20.
 
57. Yannuzzi LA, Hope-Ross M, Slakter JS, Guyer DR, Sorenson JA, Ho AC, Sperber DE, Freund KB, Orlock DA. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. Retina. 994;14(2):99-113.
 
58. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416-434.
 
59. Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, Bandello F. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2011 Sep 22. doi: 10.1111/j.1755-3768.2011.02265.x. [Epub ahead of print].
 
60. Yannuzzi LA. Degeneration: age-related macular degeneration. In: The Retinal Atlas. Philadelphia, PA: Saunders; 2010.
 
61. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization [editorial]. Retina 2008;28:375–384.
 
62. Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:89–92. 
 
63. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularised retinal pigment epithelial detachments. Arch Opthalmol 1995,113:1392–1398.
 
64. Querques G, Querques L, Forte R, Massamba N, Blanco R, Souied EH. PRECURSORS OF TYPE 3 NEOVASCULARIZATION: A Multimodal Imaging Analysis. Retina 2013 0:1–8.
 
65. Hartnett ME, Weiter JJ, Staurenghi G, et al. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103:2042–2053.
 
66. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123: 1644–1650. 
 
67. BresslerNM. Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol. 2005;123:1741–1743.
 
68. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina 2008; May 28 (5): 689-95.
 
69. Axel-Siegel R, Bourla D, Priel E, Yassur Y, Weinberger D. Angiographic and flow patterns of retinal choroidal anastomoses in age-related macular degeneration with occult choroidal neovascularization. Ophthalmology 2002; Sep 109 (9): 1726-36.
 
70. Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25(6):713–718.
 
71. Campa C, Harding SP, Pearce IA, Beare NA, Briggs MC, Heimann H.
Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye (Lond). 2010 Oct;24(10):1585-9.
 
72. Koizumi H, Iida T, Saito M, Nagayama D, Maruko I. Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 2008;246(4):515–520. 
 
73. McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011; 31(6):1043–1052. 
 
74. Kim JH, Kim JR, Kang SW, Kim SJ, Ha HS. Thinner Choroid and Greater Drusen Extent in Retinal Angiomatous Proliferation Than in Typical Exudative Age-Related Macular Degeneration. J Ophthalmol 2013;155:743–749.
 
75. Mendis R, Leslie T, McBain VA, Lois N. Combined therapy for retinal angiomatous proliferation with intravitreal triamcinolone and argon laser photocoagulation. Br J Ophthalmol 2008; 92:1154–1156. 
 
76. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferation and pigment epithelium detachment. Am J Ophthalmol 2004; 138:1077–1079.
 
77. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia G. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244: 1224–1232. 
 
78. Kuroiwa S, Arai J, Gaun S, Lida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Am J Ophthalmol 2003;23:417–420.
 
79. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fauzi AA. Long- term visual and anatomic outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol 2009;6:701–705. 
 
80. Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina. 2009 Jun;29(6):740-9. 
 
81. Rouvas AA, Papakostas TD, Ladas ID. Ranibizumab for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1719-20.
 
82. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009 Nov-Dec;29(10):1424-31.
 
83. Montero JA, Fernandez MI, Gomez-Ulla F, Ruiz-Moreno JM. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III. Eur J Ophthalmol 2009;19:448–451. 
 
84. Konstantinidis L, Mameletzi E, Mantel I, Pournovas JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009;9:1165–1171. 
 
85. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal beva-cizumab (Avastin) for retinal angiomatous proliferation. Retina 2007;27:451–457. 
 
86. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol. 2010 Jun;94(6):701-5.
 
87. Gupta B, Jyothi S, Sivaprasad S. Current treatment options for retinal angiomatous proliferans (RAP). Br J Ophthalmol. 2010 Jun;94(6):672-7.
 
88.  George S, Cooke C, Chakravarthy U. Exudative AMD subtypes and eligibility for treatment with ranibizumab. Eye (Lond). 2010 Jul;24(7):1247-51.
 
89. Atmani K, Voigt M, Le Tien V, et al. Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye 2010;24:1193–1198. 
 
90. Querques G, Rousseau A, Forte R, et al. Longitudinal anatomical response of retinal-choroidal anastomosis to antivascular endothelial growth factor therapy. Retina 2012;32:458–467.
 
91. Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation. Int Ophthalmol. 2012 Jun;32(3):259-68.
 
92. Kramann CA, Schöpfer K, Lorenz K, Zwiener I, Stoffelns BM, Pfeiffer N. Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2012 Aug;90(5):487-91.
93. Hsu TK, Liu JH, Lei J, Chao HM. Retinal angiomatous proliferation responds safely to a double dose (1.0 mg) of ranibizumab. Clin Exp Optom. 2013 Jan;96(1):112-6.
 
94. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):237-43. Epub 2007 Aug 3.
 
95. Bakri SJ, Ekdawi NS. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation.Eye (Lond). 2008 Jul;22(7):978-80. Epub 2007 Nov 23. 
 
96. Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008 Dec;146(6):935-41.e1. doi: 10.1016/j.ajo.2008.06.033. Epub 2008 Aug 23.
 
97. Montero JA, Ruiz-Moreno JM, Sanabria MR, Fernandez-Munoz M. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2009 Feb;93(2):166-70. doi: 10.1136/bjo.2008.141903. Epub 2008 Oct
29.
 
98. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A, Ladas ID. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina. 2009 Apr;29(4):536-44. 
 
99. Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):899-906. 
 
100. Lo Giudice G, Gismondi M, De Belvis V, Cian R, Tavolato M, Galan A. Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation. Retina. 2009 Jul-Aug;29(7):949-55.
 
101. Saito M, Shiragami C, Shiraga F, Kano M, Iida T. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2010 Mar;149(3):472-81
 
102. Sahu AK, Narayanan R. Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation. Retina. 2010 Jun;30(6):981.
 
103. Viola F, Mapelli C, Villani E, Tresca Carducci F, Vezzola D, Ratiglia R. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Eye (Lond). 2010 Aug;24(8):1344-51.
 
104. Lee MY, Kim KS, Lee WK. Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients: twelve-month results. Retina. 2011 Jan;31(1):65-73. 
 
105. Nakano S, Honda S, Oh H, Kita M, Negi A. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. Clin Ophthalmol. 2012;6:277-82.
 
106. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012 Mar;153(3):504-514.
 
107. Lee MY, Kim KS, Lee WK. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012 May;153(5):1004-5; author reply 1005.
 
108. Rouvas AA, Chatziralli IP, Theodossiadis PG, Moschos MM, Kotsolis AI, Ladas ID. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation. Retina.
2012 Jun;32(6):1181-9.
 
109. Shirakata Y, Shiragami C, Yamashita A, Nitta E, Fujiwara A, Shiraga F. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2012 Nov;56(6):599-607.
 
110. Saito M, Iida T, Kano M. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2013 Mar;57(2):211-20. doi: 10.1007/s10384-012-0215-7. Epub 2012 Dec 4.
 
111. Forooghian F, Cukras C, Chew EY. Retinal angiomatous proliferation complicated by pigment epithelial tear following intravitreal bevacizumab treatment.Can J Ophthalmol. 2008 Apr;43(2):246-8. 
 
112. Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, Pauleikhoff D. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye (Lond). 2011 Sep;25(9):1181-6.
 
113. Introini U, Torres Gimeno A, Scotti F, Setaccioli M, Giatsidis S, Bandello F. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1283-92.
 
114. Reche-Frutos J, Calvo-Gonzalez C, Pérez-Trigo S, Fernandez-Perez C, Donate-Lopez J, Garcia-Feijoo J. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome. Eur J Ophthalmol. 2011 Nov-Dec;21(6):783-8.
 
115. Yannuzzi LA. Idiopathic polypoidal choroidal vasculopathy. Macula Society Meeting, 1982, Miami, FL.
 
116. Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina 1990;10:9–17.
 
117. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10: 1–8.
 
118. Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopath- ologic findings in polypoidal
choroidal vasculopathy. Invest Ophthalmol Vis Sci 2008;49:4729–4737.
 
119. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recur- rent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol 1985;100:560–569.
 
120. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vascul- opathy. Arch Ophthalmol 1997;115:478–485.
 
121. Chang YC, Wu WC. Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg Lasers Imaging 2009; 40:576–581.
 
122. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal cho- roidal vasculopathy. Surv Ophthalmol 2004;49:25–37.
 
123. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthal- mol 2000;238:752–759.
 
124. Yannuzzi LA; Ciardella A, Spaide RF, Rabb M, Orlock DA. The expanding clinical spectrum of idiopatic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115: 478-85.
 
125. Spaide RF, Yannuzzi LA, Slakter JS; Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopatic polypoidal choroidal vasculopathy. Retina 1995; 15: 100-110.
 
126. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy.Br J Ophthalmol 2005; 89: 602-607.
 
127. MacCumber MW, Dastgheib K, Bressler NM, Chan CC, Harris M, Fine S et al. Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. Retina 1994; 14: 143-152.
 
128. Lafaut BA, Aisenbrey S, Van den Broecke C, Bartz-Schmidt KU, Heimann K. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration. A clinicopathologic correlation. Retina 2000; 20: 650-54.
 
129. Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy  treated with macular  translocation: clinical pathological correlation. Br J Ophthalmol 2002; 86: 321-27.
 
130. Rosa RH Jr, Davis JL, Eifrig CW, Clinicopathologic correlation of idiopatic polypoidal  choroidal vasculopathy. Arch Ophthalmol 2002; 120: 502-508.
 
131. Kuriwa S, Tateiwa H, Hisatomi T, Ishibashi T, Yoshimura N. Pathologic features of surgically excised polypoidal choroidal vasculopathy membranes. Clin Exp Ophthalmol  2004; 32: 292-302.
 
132. Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002; 86: 1093-98.
 
133. Nakajima M, Yuzawa M, Shimada H, Mori R. Correlation between indocyanine green angiographic findings and histopathology  of  polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2004; 48: 249-55.
 
134. Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, Kim H, Yuk Yau Lai T, Lee WK, Li X, Han Lim T, Ruamviboonsuk P, Sharma T, Tang S, Yuzawa M; on behalf of the Expert PCV Panel. POLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-based Guidelines for Clinical Diagnosis and Treatment. Retina. 2013 Apr;33(4):686-716.
 
135. Lee MW, Yeo I, Wong D, Ang CL. Argon laser photocoag- ulation for the treatment of polypoidal choroidal vasculop- athy. Eye (Lond) 2009;23:145–148.
 
136. R. F. Spaide, I. Donsoff, D. L. Lam et al., “Treatment of polypoidal choroidal vasculopathy with photodynamic ther- apy,” Retina, vol. 22, no. 5, pp. 529–535, 2002. 
 
137. E. Akaza, M. Yuzawa, Y. Matsumoto, S. Kashiwakura, K. Fujita, and R. Mori, “Role of photodynamic therapy in polypoidal choroidal vasculopathy,” Japanese Journal of Ophthalmology, vol. 51, no. 4, pp. 270–277, 2007. 
 
138. F. Gomi, M. Ohji, K. Sayanagi et al., “One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients,” Ophthalmology, vol. 115, no. 1, pp. 141–146, 2008. 
 
139. E. Akaza, R. Mori, and M. Yuzawa, “Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy,” Retina, vol. 28, no. 5, pp. 717–722, 2008. 
 
140. A. Otani, M. Sasahara, Y. Yodoi et al., “Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy,” American Journal of Ophthalmology, vol. 144, no. 1, pp. 7–e1, 2007.
 
141. R. M. Silva, J. Figueira, M. L. Cachulo, L. Duarte, J. R. Faria de Abreu, and J. G. Cunha-Vaz, “Polypoidal choroidal vascu- lopathy and photodynamic therapy with verteporfin,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 10, pp. 973–979, 2005.
 
142. Y. Kurashige, A. Otani, M. Sasahara et al., “Two-year results of photodynamic therapy for polypoidal choroidal vasculopa- thy,” American Journal of Ophthalmology, vol. 146, no. 4, pp. 513–e2, 2008.
 
143. Akaza, M. Yuzawa, and R. Mori, “Three-year follow-up results of photodynamic therapy for polypoidal choroidal vas- culopathy,” Japanese Journal of Ophthalmology, vol. 55, no. 1, pp. 39–44, 2011.
 
144. Kim SJ, Yu HG. “Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photo- dynamic therapy alone in polypoidal choroidal vasculopathy,” Retina, 2011. Oct;31(9):1827-34. doi: 10.1097/IAE.0b013e318214d01e.
 
145. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.Br J Ophthalmol. 2008 May;92(5):661-6. doi: 10.1136/bjo.2007.135103. Epub 2008 Mar 20.
 
146. Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.Retina. 2007 Sep;27(7):825-31
 
147. Ricci, A. Calabrese, F. Regine, F. Missiroli, and A. P. Ciardella.Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina, vol. 32, no. 7, pp. 1280–1288, 2012. 
 
148. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64.
 
149. Fernández M, Gil M, Gomez-Ulla F, Charlón P. Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup. Case Rep Med. 2012;2012:897097. doi: 10.1155/2012/897097. Epub 2012 Oct 30.
              
150. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010 Nov;150(5):666-73. doi: 10.1016/j.ajo.2010.05.035. Epub 2010 Aug 16.